

KRAS Biomarker Request





T VINCENTS PATHOLOGY	COMPET
PATIENT DETAILS	CLINICAL HISTORY
Given Name	
Address	
DOB Age Sex	
REQUESTING SPECIALIST/CONSULTANT PHYSICIAN	
Name	
Address	
Postcode	
Provider No.	
Phone	
Fax	Disease Stage:
Email	
Signature Date	TESTS REQUESTED URGENT
REFERRING PATHOLOGIST	KRAS Mutation Testing – Medicare criteria (Item 73330)
Name	Metastatic colorectal cancer may be referred for KRAS mutation
Address	testing for access to cetuximab therapy under the PBS (not applicable to public inpatients)
Postcode	
Provider No.	KRAS Mutation Testing – OTHER *
Phone	
Бах	* I understand that the cost of this testing is not covered under Medicare. Furthermore that, unless a patient consent to pay is
Email	provided, payment for this testing is the responsibility of the
Signature Date	requesting Doctor or department.
HOSPITAL STATUS OF PATIENT AT SPECIMEN COLLECTION OR DATE OF SERVICE	Requesting Dr Signature
Private patient in a private hospital or approved day hospital facility	
Private patient in a recognised hospital	
Public patient in a recognised hospital	
Outpatient of a recognised hospital	
	PLEASE SEND:
INVOICING PROCEDURE	9 unstained 3µm sections on uncoated slides or a paraffin block AND
 Bulk Bill: Copy of signed form attached Bulk Bill: Send DB3 (not appropriate for public inpatients) 	This request form completed in full AND
Bill Laboratory	 A copy of the original pathology report AND
Bill Patient (complete authorisation on reverse)	 A copy, if available, of the original surgical request form
Bill Private Health Fund:	in a padded bag to:
Membership No.	TISSUE AND MOLECULAR PATHOLOGY LEVEL 6 XAVIER BUILDING
	ST VINCENTS HOSPITAL, VICTORIA STREET
	DARLINGHURST NSW 2010
	Ph: 02 8382 9156 Fax: 02 8382 2888
MEDICARE ASSIGNMENT (Section 20A of the Health Insurance Act 1973) PRACTITIONERS USE ONLY	email: sydpathcancer@stvincents.com.au www.sydpath.com.au
TO BE COMPLETED BY THE PERSON ASSIGNMENT BENIFITS FOR THE SERVICES ON THIS FORM I offer to assign my right to benefits to the approved pathology practitioner who will render the requested pathology	
service(s) and any eligible pathologist determinable service(s) established as necessary by the practitioner.	Original Pathology Laboratory
Patient Signature Date	Block Identification Number
(Reason nation)	



MOLECULAR ASSAYS

Sydpath Pricing Information for Molecular Assays for Referring Doctors and Patients

Assay	Funding Currently Available	Cost if Unfunded
EGFR Mutation Testing	 i) Roche Access program will fund one test on previously untreated NSCLC regardless of stage. ii) Medicare item 73328 will fund one test on locally advanced or metastatic NSCLC to determine access to 2nd line gefitinib under the PBS. 	\$400.00
BRAF Mutation Testing	Roche Access program will fund one test on unresectable Stage III or IV melanoma.	\$285.00
KRAS Mutation Testing	Medicare item 73330 will fund one test on metastic colorectal carcinoma to determine access to cetuximab under the PBS.	\$232.50
SISH Testing	Medicare item 73332 will fund one HER2 ISH test on breast cancer (other than in the neoadjuvant setting) for determining access to trastuzumab under the PBS. Other SISH testing is unfunded.	\$270.00
FISH Testing	Medicare item 73332 will fund one HER2 ISH test on breast cancer (other than in the neoadjuvant setting) for determining access to trastuzumab under the PBS (usually employed in cases non-diagnostic by SISH). Other FISH testing (eg ALK, glioma FISH, sarcoma FISH, lymphoma FISH) is unfunded.	\$325.00 plus \$50 for each additional test

Please note the special requirements and clinical information needed on request form in order for us to correctly bill your patient. Costs of testing requested by a pathologist cannot be claimed under Medicare. All requests for Medicare rebated testing must include the provider number of the referring Clinician/Oncologist/Surgeon.

PATIENT AUTHORISATION

I understand that my medical practitioner has requested test(s) that are not covered by Medicare or not covered/partly covered by my private health fund.

I agree to accept responsibility for the full payment of the fees for this test(s):

Name of test(s):		
Patient's Name:	Patient's DOB:	
Patient's Address:		
Postcode:	Patient's Phone No:	
C/C Card Number:		
	Card Type: Mastercard VISA Amount to be debited: \$	
Patient's Signature: For any further informa	Date: tion required on SydPath's Billing policy for Molecular Biomarker Testing please phone 02 8382 9156	
Dear Patient, "Your doctor has recommended that you use SydPath. You are free to choose your own pathology provider. However, if your doctor has specified a particular pathologist on clinical grounds a Medicare rebate will only be payable if that pathologist performs the service. You should discuss this with your doctor" Privacy Note: The information provided will be used to assess any Medicare benifit payable for the service(s) rendered and to facilitate the proper administration of government health programs, and may be used to update enrolment records. Its collection is authorised by provisions of the Health Insurance Act 1973. The information maybe disclosed to the Department of Health and Ageing or to a person in the medical practice associated with this claim, or as authorised/required by law.		



MOLECULAR ASSAYS

Sydpath Pricing Information for Molecular Assays for Referring Doctors and Patients

Assay	Funding Currently Available	Cost if Unfunded
EGFR Mutation Testing	 i) Roche Access program will fund one test on previously untreated NSCLC regardless of stage. ii) Medicare item 73328 will fund one test on locally advanced or metastatic NSCLC to determine access to 2nd line gefitinib under the PBS. 	\$400.00
BRAF Mutation Testing	Roche Access program will fund one test on unresectable Stage III or IV melanoma.	\$285.00
KRAS Mutation Testing	Medicare item 73330 will fund one test on metastic colorectal carcinoma to determine access to cetuximab under the PBS.	\$232.50
SISH Testing	Medicare item 73332 will fund one HER2 ISH test on breast cancer (other than in the neoadjuvant setting) for determining access to trastuzumab under the PBS. Other SISH testing is unfunded.	\$270.00
FISH Testing	Medicare item 73332 will fund one HER2 ISH test on breast cancer (other than in the neoadjuvant setting) for determining access to trastuzumab under the PBS (usually employed in cases non-diagnostic by SISH). Other FISH testing (eg ALK, glioma FISH, sarcoma FISH, lymphoma FISH) is unfunded.	\$325.00 plus \$50 for each additional test

Please note the special requirements and clinical information needed on request form in order for us to correctly bill your patient. Costs of testing requested by a pathologist cannot be claimed under Medicare. All requests for Medicare rebated testing must include the provider number of the referring Clinician/Oncologist/Surgeon.

PATIENT AUTHORISATION

I understand that my medical practitioner has requested test(s) that are not covered by Medicare or not covered/partly covered by my private health fund.

I agree to accept responsibility for the full payment of the fees for this test(s):

Name of test(s):		
Patient's Name:	Patient's DOB:	
Patient's Address:		
Postcode:	Patient's Phone No:	
C/C Card Number:		
	Card Type: Mastercard VISA Amount to be debited: \$	
Patient's Signature: For any further informa	Date: tion required on SydPath's Billing policy for Molecular Biomarker Testing please phone 02 8382 9156	
Dear Patient, "Your doctor has recommended that you use SydPath. You are free to choose your own pathology provider. However, if your doctor has specified a particular pathologist on clinical grounds a Medicare rebate will only be payable if that pathologist performs the service. You should discuss this with your doctor" Privacy Note: The information provided will be used to assess any Medicare benifit payable for the service(s) rendered and to facilitate the proper administration of government health programs, and may be used to update enrolment records. Its collection is authorised by provisions of the Health Insurance Act 1973. The information maybe disclosed to the Department of Health and Ageing or to a person in the medical practice associated with this claim, or as authorised/required by law.		